메뉴 건너뛰기




Volumn 20, Issue 10, 2016, Pages 575-580

Rolling out efavirenz for HIV precision medicine in Africa: Are we ready for pharmacovigilance and tackling neuropsychiatric adverse effects?

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ; ANTIRETROVIRUS AGENT; BENZOXAZINE DERIVATIVE;

EID: 84991453598     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2016.0120     Document Type: Article
Times cited : (28)

References (52)
  • 1
    • 84880115294 scopus 로고    scopus 로고
    • Prevalence, characteristics and correlates of a positive-dementia screen in patients on antiretroviral therapy in Bamenda, Cameroon: A cross-sectional study
    • Atashili J, Gaynes BN, Pence BW, et al. (2013). Prevalence, characteristics and correlates of a positive-dementia screen in patients on antiretroviral therapy in Bamenda, Cameroon: A cross-sectional study. BMC Neurol 13, 86.
    • (2013) BMC Neurol , vol.13 , pp. 86
    • Atashili, J.1    Gaynes, B.N.2    Pence, B.W.3
  • 2
    • 0034802777 scopus 로고    scopus 로고
    • The sensitivity and specificity of the major depression inventory, using a present state examination as the index of diagnostic validity
    • Bech P, Rasmussen NA, Olsen LR, Noerholm V, and Abildgaard W. (2001). The sensitivity and specificity of the Major Depression Inventory, using a Present State Examination as the index of diagnostic validity. J Affect Disord 66, 159-164.
    • (2001) J Affect Disord , vol.66 , pp. 159-164
    • Bech, P.1    Rasmussen, N.A.2    Olsen, L.R.3    Noerholm, V.4    Abildgaard, W.5
  • 4
    • 77951876879 scopus 로고    scopus 로고
    • HIV-subtype A is associated with poorer neuropsychological performance compared with subtype D in antiretroviral therapy-naive Ugandan children
    • Boivin MJ, Ruel TD, Boal HE, et al. (2010). HIV-subtype A is associated with poorer neuropsychological performance compared with subtype D in antiretroviral therapy-naive Ugandan children. AIDS 24, 1163-1170.
    • (2010) AIDS , vol.24 , pp. 1163-1170
    • Boivin, M.J.1    Ruel, T.D.2    Boal, H.E.3
  • 5
    • 84862752706 scopus 로고    scopus 로고
    • Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: A consensus statement
    • and the participants of Conference on Antiretroviral Drug Optimization.
    • Crawford KW, Ripin DH, Levin AD, Campbell JR, Flexner C, and the participants of Conference on Antiretroviral Drug Optimization. (2012). Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: A consensus statement. Lancet Infect Dis 12, 550-560.
    • (2012) Lancet Infect Dis , vol.12 , pp. 550-560
    • Crawford, K.W.1    Ripin, D.H.2    Levin, A.D.3    Campbell, J.R.4    Flexner, C.5
  • 6
    • 28144452516 scopus 로고    scopus 로고
    • Impact on neuropsychological performance and symptoms in HIV-infected individuals
    • Clifford DB, Evans S, Yang Y, et al. (2005). Impact on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 143, 714-721.
    • (2005) Ann Intern Med , vol.143 , pp. 714-721
    • Clifford, D.B.1    Evans, S.2    Yang, Y.3
  • 7
    • 79955458684 scopus 로고    scopus 로고
    • Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients
    • Ciccarelli N, Fabbiani M, Di Giambenedetto S, et al. (2011). Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 76, 1403-1409.
    • (2011) Neurology , vol.76 , pp. 1403-1409
    • Ciccarelli, N.1    Fabbiani, M.2    Di Giambenedetto, S.3
  • 8
    • 33746711007 scopus 로고    scopus 로고
    • What is the relevance of mental health to HIV/AIDS care and treatment programs in developing countries? A systematic review
    • Collins PY, Holman AR, Freeman MC, and Patel V. (2006). What is the relevance of mental health to HIV/AIDS care and treatment programs in developing countries? A systematic review. AIDS 20, 1571-1582.
    • (2006) AIDS , vol.20 , pp. 1571-1582
    • Collins, P.Y.1    Holman, A.R.2    Freeman, M.C.3    Patel, V.4
  • 9
    • 84886636044 scopus 로고    scopus 로고
    • Neuronal toxicity of efavirenz: A systematic review
    • Decloedt EH, and Maartens G. (2013). Neuronal toxicity of efavirenz: A systematic review. Expert Opin Drug Saf 12, 841-846.
    • (2013) Expert Opin Drug Saf , vol.12 , pp. 841-846
    • Decloedt, E.H.1    Maartens, G.2
  • 10
    • 84894042969 scopus 로고    scopus 로고
    • Genetic variants of drug metabolizing enzymes and drug transporter (ABCB1) as possible biomarkers for adverse drug reactions in an HIV/AIDS cohort in Zimbabwe
    • Dhoro M, Ngara B, Kadzirange G, Nhachi C, and Masimirembwa C. (2013). Genetic variants of drug metabolizing enzymes and drug transporter (ABCB1) as possible biomarkers for adverse drug reactions in an HIV/AIDS cohort in Zimbabwe. Curr HIV Res 11, 481-490.
    • (2013) Curr HIV Res , vol.11 , pp. 481-490
    • Dhoro, M.1    Ngara, B.2    Kadzirange, G.3    Nhachi, C.4    Masimirembwa, C.5
  • 11
    • 84938885862 scopus 로고    scopus 로고
    • CYP2B66, CYP2B618, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: Population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe
    • Dhoro M, Zvada S, Ngara B, et al. (2015). CYP2B66, CYP2B618, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: Population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe. BMC Pharmacol Toxicol 16, 4.
    • (2015) BMC Pharmacol Toxicol , vol.16 , pp. 4
    • Dhoro, M.1    Zvada, S.2    Ngara, B.3
  • 12
    • 74549150032 scopus 로고    scopus 로고
    • Treatment modification in human immune deficiency virus infected individuals starting combination antiretroviral therapy between 2005 and 2008
    • Elzi L, Marzolini C, Furrer H, et al. (2010). Treatment modification in human immune deficiency virus infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 170, 57-65.
    • (2010) Arch Intern Med , vol.170 , pp. 57-65
    • Elzi, L.1    Marzolini, C.2    Furrer, H.3
  • 13
    • 84899620845 scopus 로고    scopus 로고
    • Efficacy of 400 mf efavirenz versus standard 600 mg dose in HIVinfected, antiretroviral-naïve adults (ENCORE1): A randomized, double-blind, placebo-controlled, non-inferiority trial
    • ENCORE Study Group
    • ENCORE Study Group, Puls R, Amin J, et al. (2014). Efficacy of 400 mf efavirenz versus standard 600 mg dose in HIVinfected, antiretroviral-naïve adults (ENCORE1): A randomized, double-blind, placebo-controlled, non-inferiority trial. Lancet 383, 1474-1482.
    • (2014) Lancet , vol.383 , pp. 1474-1482
    • Puls, R.1    Amin, J.2
  • 14
    • 0036499964 scopus 로고    scopus 로고
    • Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens
    • Fumaz CR, Tuldra A, Ferrrer MJ, et al. (2002). Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr 29, 244-253.
    • (2002) J Acquir Immune Defic Syndr , vol.29 , pp. 244-253
    • Fumaz, C.R.1    Tuldra, A.2    Ferrrer, M.J.3
  • 15
    • 84962569327 scopus 로고    scopus 로고
    • A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications
    • Gaida R, Truter I, Grobler C, Kotze T, and Godman B. (2016). A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications. Expert Rev Anti Infect Ther 14, 377-388.
    • (2016) Expert Rev Anti Infect Ther , vol.14 , pp. 377-388
    • Gaida, R.1    Truter, I.2    Grobler, C.3    Kotze, T.4    Godman, B.5
  • 16
    • 35348923463 scopus 로고    scopus 로고
    • Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 6 and 26
    • Gatanaga H, Hayashida T, Tsuschiya K, et al. (2007). Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 6 and 26. Clin Infect Dis 45, 1230-1237.
    • (2007) Clin Infect Dis , vol.45 , pp. 1230-1237
    • Gatanaga, H.1    Hayashida, T.2    Tsuschiya, K.3
  • 17
    • 77955694290 scopus 로고    scopus 로고
    • Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients
    • Gounden V, van Niekerk C, Snyman T, and George JA. (2010). Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther 7, 32.
    • (2010) AIDS Res Ther , vol.7 , pp. 32
    • Gounden, V.1    Van Niekerk, C.2    Snyman, T.3    George, J.A.4
  • 18
    • 28044459173 scopus 로고    scopus 로고
    • Prediction of neuropsychiatric adverse events associated with long-Term efavirenz therapy, using plasma drug level monitoring
    • Gutiérrez F, Navarro A, Padilla S, et al. (2005). Prediction of neuropsychiatric adverse events associated with long-Term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 41, 1 648-653.
    • (2005) Clin Infect Dis , vol.41 , Issue.1 , pp. 648-653
    • Gutiérrez, F.1    Navarro, A.2    Padilla, S.3
  • 19
    • 19944428456 scopus 로고    scopus 로고
    • Pharmacogenetics of efavirenz and central nervous system side effects: An Adult Clinical Trials Group study
    • Haas DW, Ribaudo HJ, Kim RB, et al. (2004). Pharmacogenetics of efavirenz and central nervous system side effects: An Adult Clinical Trials Group study. AIDS 18, 2391-2400
    • (2004) AIDS , vol.18 , pp. 2391-2400
    • Haas, D.W.1    Ribaudo, H.J.2    Kim, R.B.3
  • 20
    • 84975166371 scopus 로고    scopus 로고
    • White matter micro-structural changes in ART-naive and ART-Treated children and adolescents infected with HIV in South Africa
    • Hoare J, Fouche JP, Phillips N, et al. (2015). White matter micro-structural changes in ART-naive and ART-Treated children and adolescents infected with HIV in South Africa. AIDS 29, 793-801.
    • (2015) AIDS , vol.29 , pp. 793-801
    • Hoare, J.1    Fouche, J.P.2    Phillips, N.3
  • 21
    • 84902573941 scopus 로고    scopus 로고
    • HIV associated neurocognitive disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: A cross sectional study
    • Kelly CM, van Oosterhout JJ, Ngwalo C, et al. (2014). HIV associated neurocognitive disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: A cross sectional study. PLoS One 9, e98962.
    • (2014) PLoS One , vol.9 , pp. e98962
    • Kelly, C.M.1    Van Oosterhout, J.J.2    Ngwalo, C.3
  • 22
    • 84880291960 scopus 로고    scopus 로고
    • Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects
    • Leutscher P, Secher C, Storgaard M, and Larsen CS. (2013). Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects. Scand J Infect Dis 45, 645-41.
    • (2013) Scand J Infect Dis , vol.45 , pp. 645-741
    • Leutscher, P.1    Secher, C.2    Storgaard, M.3    Larsen, C.S.4
  • 23
    • 0037271311 scopus 로고    scopus 로고
    • Long-Term assessment of neuropsychiatric adverse reactions associated with efavirenz
    • Lochet P, Pevriere H, Lotthé A, Mauboussin JM, Delmas B, and Revnes J. (2003). Long-Term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med 4, 62-66
    • (2003) HIV Med , vol.4 , pp. 62-66
    • Lochet, P.1    Pevriere, H.2    Lotthé, A.3    Mauboussin, J.M.4    Delmas, B.5    Revnes, J.6
  • 24
    • 79851482408 scopus 로고    scopus 로고
    • Association of pharmacogenetics markers with premature discontinuation of first-line anti-HIV therapy: An observational cohort study
    • Lubomirov R, Colombo S, di Iulio J, et al. (2011). Association of pharmacogenetics markers with premature discontinuation of first-line anti-HIV therapy: An observational cohort study. J Infect Dis 203, 246-257.
    • (2011) J Infect Dis , vol.203 , pp. 246-257
    • Lubomirov, R.1    Colombo, S.2    Di Iulio, J.3
  • 25
    • 84903151392 scopus 로고    scopus 로고
    • Dose reduction of efavirenz: An observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics
    • Martin AS, Gómez AL, Garcia-Berrocal B, et al. (2014). Dose reduction of efavirenz: An observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics. Pharmacogenomics 15, 997-1006.
    • (2014) Pharmacogenomics , vol.15 , pp. 997-1006
    • Martin, A.S.1    Gómez, A.L.2    Garcia-Berrocal, B.3
  • 26
    • 0035875828 scopus 로고    scopus 로고
    • Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients
    • Marzolini C Telenti A, Decosterd LA, et al. (2001). Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS 15:71-75.
    • (2001) AIDS , vol.15 , pp. 71-75
    • Marzolini, C.1    Telenti, A.2    Decosterd, L.A.3
  • 27
    • 84941029178 scopus 로고    scopus 로고
    • Effects of CYP2B6 and CYP1A2 genetic variation on nevirapine plasma concentration and pharmacodynamics as measured by CD4 Cell count in Zimbabwean HIV-infected patients
    • Mhandire D, Lacerda M, Castel S, et al. (2015). Effects of CYP2B6 and CYP1A2 genetic variation on nevirapine plasma concentration and pharmacodynamics as measured by CD4 Cell count in Zimbabwean HIV-infected patients. OMICS 19, 553-562.
    • (2015) OMICS , vol.19 , pp. 553-562
    • Mhandire, D.1    Lacerda, M.2    Castel, S.3
  • 28
    • 84903599799 scopus 로고    scopus 로고
    • Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: An analysis of trial data
    • Mollan KR, Smurzynski M, Eron JJ, et al. (2014). Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: An analysis of trial data. Ann Intern Med 161, 1-10.
    • (2014) Ann Intern Med , vol.161 , pp. 1-10
    • Mollan, K.R.1    Smurzynski, M.2    Eron, J.J.3
  • 29
    • 84966349291 scopus 로고    scopus 로고
    • CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population
    • Mukonzo JK, Bisaso RK, Ogwal-Okeng J, Gustafsson LL, Owen JS, and Aklillu E. (2016). CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population. Pharmacogenomics 17, 603-613.
    • (2016) Pharmacogenomics , vol.17 , pp. 603-613
    • Mukonzo, J.K.1    Bisaso, R.K.2    Ogwal-Okeng, J.3    Gustafsson, L.L.4    Owen, J.S.5    Aklillu, E.6
  • 30
    • 84878378977 scopus 로고    scopus 로고
    • Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV patients with or without tuberculosis: A prospective cohort study
    • Mukonzo JK, Okwera A, Nakasujja N, et al. (2013). Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV patients with or without tuberculosis: A prospective cohort study. BMC Infect Dis 13, 261.
    • (2013) BMC Infect Dis , vol.13 , pp. 261
    • Mukonzo, J.K.1    Okwera, A.2    Nakasujja, N.3
  • 31
    • 84900337388 scopus 로고    scopus 로고
    • Pharmacogenetic-based efavirenz dose modification: Suggestions for an African population and the different CYP2B6 genotypes
    • Mukonzo JK, Owen JS, Ogwal-Okeng J, et al. (2014). Pharmacogenetic-based efavirenz dose modification: Suggestions for an African population and the different CYP2B6 genotypes. PLoS One 9, e86919.
    • (2014) PLoS One , vol.9 , pp. e86919
    • Mukonzo, J.K.1    Owen, J.S.2    Ogwal-Okeng, J.3
  • 32
    • 84898620408 scopus 로고    scopus 로고
    • Changes to antiretroviral drug regimens during integrated TB-HIV treatment: Results of the SAPiT trial
    • Naidoo A, Naidoo K, Yende-Zuma N, et al. (2014). Changes to antiretroviral drug regimens during integrated TB-HIV treatment: Results of the SAPiT trial. Antivir Ther 19, 161-169.
    • (2014) Antivir Ther , vol.19 , pp. 161-169
    • Naidoo, A.1    Naidoo, K.2    Yende-Zuma, N.3
  • 33
    • 84858002034 scopus 로고    scopus 로고
    • Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans
    • Nanzigu S, Eriksen J, Makumbi F, et al. (2012). Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans. HIV Med 13, 193-201.
    • (2012) HIV Med , vol.13 , pp. 193-201
    • Nanzigu, S.1    Eriksen, J.2    Makumbi, F.3
  • 34
    • 84879830246 scopus 로고    scopus 로고
    • Evaluation of the prevalence, progression and severity of common adverse reactions (lipodystrophy, CNS, peripheral neuropathy, and hypersensitivity reactions) associated with anti-retroviral therapy (ART) and anti-Tuberculosis treatment in outpatients in Zimbabwe
    • Nemaura T, Dhoro M, Nhachi C, Kadzirange G, Chonzi P, and Masimirembwa C. (2013). Evaluation of the prevalence, progression and severity of common adverse reactions (lipodystrophy, CNS, peripheral neuropathy, and hypersensitivity reactions) associated with anti-retroviral therapy (ART) and anti-Tuberculosis treatment in outpatients in Zimbabwe. J AIDS Clin Res 4, 4.
    • (2013) J AIDS Clin Res , vol.4 , pp. 4
    • Nemaura, T.1    Dhoro, M.2    Nhachi, C.3    Kadzirange, G.4    Chonzi, P.5    Masimirembwa, C.6
  • 35
    • 84879813185 scopus 로고    scopus 로고
    • Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: A parallel-group prespective cohort study in two Sub-Saharan Africa populations
    • Ngaimisi E, Habtewold A, Minzi O, et al. (2013). Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: A parallel-group prespective cohort study in two Sub-Saharan Africa populations. PLoS One 8, e67964
    • (2013) PLoS One , vol.8 , pp. e67964
    • Ngaimisi, E.1    Habtewold, A.2    Minzi, O.3
  • 36
    • 84939157262 scopus 로고    scopus 로고
    • CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B69 andCYP2B618 distribution in HIV-exposed subjects from Dschang, Western Cameroon
    • Paganotti GM, Russo G, Sobze MS, et al. (2015). CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B69 andCYP2B618 distribution in HIV-exposed subjects from Dschang, Western Cameroon. Infect Genet Evol 35, 122-126.
    • (2015) Infect Genet Evol , vol.35 , pp. 122-126
    • Paganotti, G.M.1    Russo, G.2    Sobze, M.S.3
  • 37
    • 0035986092 scopus 로고    scopus 로고
    • Safety and tolerance of efavirenz in different antiretroviral regimens: Results from a national multicenter prospective study in 1, 033 HIV-infected patients
    • Pérez-Molina JA. (2002). Safety and tolerance of efavirenz in different antiretroviral regimens: Results from a national multicenter prospective study in 1, 033 HIV-infected patients. HIV Clin Trials 3, 279-286.
    • (2002) HIV Clin Trials , vol.3 , pp. 279-286
    • Pérez-Molina, J.A.1
  • 38
    • 84956818202 scopus 로고    scopus 로고
    • Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: The role of CYP2B6 genetic variation
    • Pinillos F, Dandara C, Swart M, et al. (2015). Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: The role of CYP2B6 genetic variation. BMC Infect Dis 16, 56.
    • (2015) BMC Infect Dis , vol.16 , pp. 56
    • Pinillos, F.1    Dandara, C.2    Swart, M.3
  • 39
    • 33847791464 scopus 로고    scopus 로고
    • Quality of life and depression among HIV-infected patients receiving efavirenz-or protease inhibitor-based therapy in Senegal
    • Poupard M, Ngom Gueye NF, Thiam D, et al. (2007). Quality of life and depression among HIV-infected patients receiving efavirenz-or protease inhibitor-based therapy in Senegal. HIV Med 8, 92-95.
    • (2007) HIV Med , vol.8 , pp. 92-95
    • Poupard, M.1    Ngom Gueye, N.F.2    Thiam, D.3
  • 40
    • 72449130446 scopus 로고    scopus 로고
    • Depression in patients with HIV is underdiagnosed: A cross-sectional study in Denmark
    • Rodkjaer L, Laursen T, Christensen NB, and Sodemann M. (2010). Depression in patients with HIV is underdiagnosed: A cross-sectional study in Denmark. HIV Medicine 11, 46-53.
    • (2010) HIV Medicine , vol.11 , pp. 46-53
    • Rodkjaer, L.1    Laursen, T.2    Christensen, N.B.3    Sodemann, M.4
  • 41
    • 84948988283 scopus 로고    scopus 로고
    • Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice
    • Schackman BR, Haas DW, Park SS, Li XC, and Freedberg KA. (2015). Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice. Pharmacogenomics 16, 2007-2018.
    • (2015) Pharmacogenomics , vol.16 , pp. 2007-2018
    • Schackman, B.R.1    Haas, D.W.2    Park, S.S.3    Li, X.C.4    Freedberg, K.A.5
  • 42
    • 84863722466 scopus 로고    scopus 로고
    • Discontinuation of Atripla as first-line therapy in HIV-1 infected patients
    • Scourfield A, Zheng J, Chinthapalli S, et al. (2012). Discontinuation of Atripla as first-line therapy in HIV-1 infected patients. AIDS 26, 1399-1401.
    • (2012) AIDS , vol.26 , pp. 1399-1401
    • Scourfield, A.1    Zheng, J.2    Chinthapalli, S.3
  • 43
    • 84961652499 scopus 로고    scopus 로고
    • An expanded analysis of pharmacogenetics determinants of efavirenz response that includes 3¢-UTR single nucleotide polymorphisms among Black South African HIV/AIDS patients
    • Swart M, Evans J, Skelton M, et al. (2016). An expanded analysis of pharmacogenetics determinants of efavirenz response that includes 3¢-UTR single nucleotide polymorphisms among Black South African HIV/AIDS patients. Front Genet 6, 356.
    • (2016) Front Genet , vol.6 , pp. 356
    • Swart, M.1    Evans, J.2    Skelton, M.3
  • 44
    • 84880922434 scopus 로고    scopus 로고
    • High predictive value of CYP2B6 SNPs for steadystate plasma efavirenz levels in South African HIV/AIDS patients
    • Swart M, Skelton M, Ren Y, Smith P, Takuva S, and Dandara C. (2013). High predictive value of CYP2B6 SNPs for steadystate plasma efavirenz levels in South African HIV/AIDS patients. Pharmacogenet Genomics 23, 415-427.
    • (2013) Pharmacogenet Genomics , vol.23 , pp. 415-427
    • Swart, M.1    Skelton, M.2    Ren, Y.3    Smith, P.4    Takuva, S.5    Dandara, C.6
  • 45
    • 84886594096 scopus 로고    scopus 로고
    • Severe toxicity and polymerase-c gene abnormalities in Malawian adults on stavudine-based antiretroviral therapy
    • van Oosterhout JJ, Gardner K, Mallewa J, et al. (2013). Severe toxicity and polymerase-c gene abnormalities in Malawian adults on stavudine-based antiretroviral therapy. Pharmacogenet Genomics 23, 624-626.
    • (2013) Pharmacogenet Genomics , vol.23 , pp. 624-626
    • Van Oosterhout, J.J.1    Gardner, K.2    Mallewa, J.3
  • 47
    • 33644588715 scopus 로고    scopus 로고
    • Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz
    • Wang J, Sönnerborg A, Rane A, et al. (2006). Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 16, 191-198.
    • (2006) Pharmacogenet Genomics , vol.16 , pp. 191-198
    • Wang, J.1    Sönnerborg, A.2    Rane, A.3
  • 48
    • 33748874526 scopus 로고    scopus 로고
    • Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events
    • Ward DJ, and Curtin JM. (2006). Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events. AIDS Patient Care STDS 20, 542-548.
    • (2006) AIDS Patient Care STDS , vol.20 , pp. 542-548
    • Ward, D.J.1    Curtin, J.M.2
  • 49
    • 84922740654 scopus 로고    scopus 로고
    • The global burden of mental, neurological, and substance use disorders: An analysis from the Global Burden of Disease Study 2010
    • Whiteford HA Ferrari AJ, Degenhardt L, Feigin V, and Vos T. (2015). The global burden of mental, neurological, and substance use disorders: An analysis from the Global Burden of Disease Study 2010. PLoS One 10(2):e0116820.
    • (2015) PLoS One , vol.10 , Issue.2 , pp. e0116820
    • Whiteford, H.A.1    Ferrari, A.J.2    Degenhardt, L.3    Feigin, V.4    Vos, T.5
  • 52
    • 84929081635 scopus 로고    scopus 로고
    • 90-90-90 An ambitious treatment target to help end the AIDS epidemic
    • UNAIDS.
    • UNAIDS. (2014). 90-90-90 An ambitious treatment target to help end the AIDS epidemic. Joint United Nations Programme on HIV/AIDS (UNAIDS).
    • (2014) Joint United Nations Programme on HIV/AIDS (UNAIDS)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.